Jane Street’s Keros Therapeutics KROS Stock Holding History

Jane Street’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-27,000	Closed	-$298K	–	12426
2026 Q1	$298K	Buy	+27,000	New	+$417K	﹤0.01%	9255
2025 Q4	–	Sell	-65,000	Closed	-$1.03M	–	11818
2025 Q3	$1.03M	Sell	65,000 -48,100	-43%	-$711K	﹤0.01%	6260
2025 Q2	$1.51M	Sell	113,100 -23,300	-17%	-$315K	﹤0.01%	4882
2025 Q1	$1.39M	Sell	136,400 -373,100	-73%	-$4.33M	﹤0.01%	4966
2024 Q4	$8.07M	Buy	+509,500	New	+$26.5M	﹤0.01%	2091
2024 Q2	–	Sell	-5,500	Closed	-$364K	–	9826
2024 Q1	$364K	Buy	+5,500	New	+$326K	﹤0.01%	7239

Other funds holding KROS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Jane Street's KROS Position: Q2 2026 in Review

Jane Street increased its Keros Therapeutics (KROS) stake by 159% in Q2 2026, buying an estimated $789K and bringing the position to 115,267 shares worth $1.23M. The position accounts for ﹤0.01% of the portfolio, ranked #6098.

Jane Street first reported a position in KROS in Q2 2020 and has held it in 16 quarters since. The position peaked at $3.49M in Q3 2024. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

Jane Street held 115,267 shares of Keros Therapeutics worth $1.23M as of Q2 2026.
Jane Street bought 70,810 Keros Therapeutics shares in Q2 2026, an estimated $789K.
Keros Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #6098 holding.
Jane Street first reported a position in Keros Therapeutics in Q2 2020 and has held it in 16 quarters since.
Jane Street's Keros Therapeutics position peaked at $3.49M in Q3 2024.
132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.